Market Place
Sourcing Support
Neuronetics Reports Q1 2026 Results, Hosts Earnings Call
21 Apr 2026 //
GLOBENEWSWIRE
Optum Expands NeuroStar TMS Coverage to PMHNPs
13 Apr 2026 //
GLOBENEWSWIRE
Neuronetics Comments On Letter From Pointillist Family Office
07 Apr 2026 //
GLOBENEWSWIRE
Neuronetics Announces Chief Financial Officer Transition
06 Apr 2026 //
GLOBENEWSWIRE
Neuronetics Names Dan Reuvers President & CEO
17 Mar 2026 //
GLOBENEWSWIRE
Neuronetics Unveils 2025 Q4 And Full-Year Financial Results
17 Mar 2026 //
GLOBENEWSWIRE
Neuronetics Reports Q4 2025 Results, Hosts Earnings Call
03 Mar 2026 //
GLOBENEWSWIRE
Neuronetics Reveals 2025 Q4 And Full-Year Financials
10 Feb 2026 //
GLOBENEWSWIRE
Neuronetics Joins Piper Sandler Healthcare Conference
20 Nov 2025 //
GLOBENEWSWIRE
Mile Marker Wins 2025 Healthcare Marketing Impact Award
13 Nov 2025 //
PR NEWSWIRE
TRICARE West Covers NeuroStar TMS for Depressed Teens 15+year
12 Nov 2025 //
GLOBENEWSWIRE
Neuronetics Reveals Q3 2025 Results & CEO Transition Plan
04 Nov 2025 //
GLOBENEWSWIRE
Neuronetics Issues Inducement Grant Per Nasdaq LR 5635(C)(4)
31 Oct 2025 //
GLOBENEWSWIRE
Neuronetics Inks 3-Year Exclusive Partnership With Elite DNA
30 Oct 2025 //
GLOBENEWSWIRE
Neuronetics To Present Q3 2025 Results And Conduct Conference
21 Oct 2025 //
GLOBENEWSWIRE
NY Medicaid Expands TMS Therapy Coverage for MDD Patients
17 Sep 2025 //
GLOBENEWSWIRE
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule
06 Aug 2025 //
GLOBENEWSWIRE
Neuronetics Unveils Q2 2025 Financials and Operations
05 Aug 2025 //
GLOBENEWSWIRE
Neuronetics to present at Canaccord Genuity 45th Conference
04 Aug 2025 //
GLOBENEWSWIRE
Neuronetics to Report Q2 2025 Results, Host Conference Call
22 Jul 2025 //
GLOBENEWSWIRE
Neuronetics Names New Chief Financial Officer
15 Jul 2025 //
GLOBENEWSWIRE
Neuronetics Reports Inducement Grant Under Nasdaq Rule 5635(c)(4)
19 Jun 2025 //
GLOBENEWSWIRE
Neuronetics to Join TMS 2025, Updates on Care Trial
10 Jun 2025 //
GLOBENEWSWIRE
Neuronetics Set to Join Russell 2000® & Russell 3000® Indexes
02 Jun 2025 //
GLOBENEWSWIRE
Neuronetics Launches National TMS Therapy Awareness Day
14 May 2025 //
GLOBENEWSWIRE
Neuronetics Reports Q1 2025 Financial Results
06 May 2025 //
GLOBENEWSWIRE
Neuronetics Reports Grant Under Nasdaq Rule 5635(c)(4)
05 May 2025 //
GLOBENEWSWIRE
Neuronetics to Report Q1 2025 Results, Host Conference Call
22 Apr 2025 //
GLOBENEWSWIRE
Evernorth Health Services, a Cigna Company, Expands NeuroStar TMS
31 Mar 2025 //
GLOBENEWSWIRE
Neuronetics Reports Q4 and Full Year 2024 Financial Results
27 Mar 2025 //
GLOBENEWSWIRE
Neuronetics Reports Q4, Full-Year 2024 Financial, Operating Results
04 Mar 2025 //
GLOBENEWSWIRE
Neuronetics Reports Inducement Grant Under Nasdaq LR 5635(c)(4)
03 Mar 2025 //
GLOBENEWSWIRE
Neuronetics to Report Q4 2024 Financial and Operating Results
21 Feb 2025 //
GLOBENEWSWIRE
Neuronetics Prices $18M Public Offering Of Common Stock
07 Feb 2025 //
GLOBENEWSWIRE
Neuronetics Reports Inducement Grant Under Nasdaq LR 5635(c)(4)
07 Feb 2025 //
GLOBENEWSWIRE
Neuronetics Launches Underwritten Public Offering of Stock
06 Feb 2025 //
GLOBENEWSWIRE
NeuroStar Unveils 2 Significant Publications on TMS Therapy
29 Jan 2025 //
GLOBENEWSWIRE
Neuronetics Provides Business Update and Issues 2025 Guidance
13 Jan 2025 //
GLOBENEWSWIRE
Neuronetics Reports Inducement Grant Under Nasdaq LR 5635(c)(4)
18 Dec 2024 //
GLOBENEWSWIRE
Neuronetics Reports Nasdaq Inducement Grant
16 Dec 2024 //
GLOBENEWSWIRE
Neuronetics and Greenbrook TMS Announce Closing of Transaction
10 Dec 2024 //
GLOBENEWSWIRE
Neuronetics To Present At Piper Sandler 36th Healthcare Conference
20 Nov 2024 //
GLOBENEWSWIRE
Neuronetics Reports Inducement Grant Under Nasdaq LR 5635(c)(4)
12 Nov 2024 //
GLOBENEWSWIRE
Neuronetics Reports Record Q3 2024 Financial & Operating Results
12 Nov 2024 //
GLOBENEWSWIRE
Neuronetics to Report Q3 2024 Results and Host Call
29 Oct 2024 //
GLOBENEWSWIRE
NeuroStar Presents at AACAP 2024 on TMS and Depression
14 Oct 2024 //
GLOBENEWSWIRE
HCSC Adds TMS Coverage For Adolescents
25 Sep 2024 //
GLOBENEWSWIRE
Expanded Health Policies Enhance TMS Therapy Access
19 Sep 2024 //
GLOBENEWSWIRE
NeuroStar® Releases Software Upgrades to Elevate Patient Care
16 Sep 2024 //
GLOBENEWSWIRE
NeuroStar Honors Suicide Prevention Month with Milestone Achievement
03 Sep 2024 //
GLOBENEWSWIRE
NeuroStar® Marks Two Years of Transformative Impact with NeuroStar University
20 Aug 2024 //
GLOBENEWSWIRE
Neuronetics Reports Record Second Quarter 2024 Financial and Operating Results
12 Aug 2024 //
GLOBENEWSWIRE
Neuronetics and Greenbrook TMS Announce Definitive Agreement to Merge
12 Aug 2024 //
GLOBENEWSWIRE
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
05 Aug 2024 //
GLOBENEWSWIRE
NeuroStar Partners With This Is My Brave to Recognize Teen Mental Health Month
01 Aug 2024 //
GLOBENEWSWIRE
Neuronetics to Present at the Canaccord Genuity 44th Annual Growth Conference
31 Jul 2024 //
GLOBENEWSWIRE
Neuronetics Closes $90M Credit Facility With Perceptive Advisors
30 Jul 2024 //
GLOBENEWSWIRE
Neuronetics To Report Q2 2024 Results And Host Conference Call
29 Jul 2024 //
GLOBENEWSWIRE
Aetna Policy Update Expands TMS Availability for Adolescents With Depression
22 Jul 2024 //
GLOBENEWSWIRE
California Medicaid Adds TMS Access for 14.8 Million Adolescents and Adults
11 Jul 2024 //
GLOBENEWSWIRE
